Traws Pharma (NASDAQ:TRAW) Trading 4.8% Higher – Here’s Why

Traws Pharma, Inc. (NASDAQ:TRAW)’s stock price rose 4.8% during mid-day trading on Monday . The company traded as high as $0.4871 and last traded at $0.4716. 94,244 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 137,096 shares. The stock had previously closed at $0.45.

Analysts Set New Price Targets

TRAW has been the topic of several recent analyst reports. Citigroup downgraded shares of Traws Pharma to a “neutral” rating in a report on Monday, June 15th. HC Wainwright restated a “negative” rating and set a $1.00 price target on shares of Traws Pharma in a report on Thursday, June 18th. LADENBURG THALM/SH SH downgraded Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Weiss Ratings lowered Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Finally, Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. Three investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Traws Pharma has a consensus rating of “Reduce” and a consensus price target of $1.00.

Traws Pharma Stock Up 0.1%

The firm has a 50-day moving average price of $0.87 and a two-hundred day moving average price of $1.46. The company has a market capitalization of $8.39 million, a P/E ratio of -0.33 and a beta of 1.57.

Traws Pharma (NASDAQ:TRAW) last announced its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.39. On average, analysts predict that Traws Pharma, Inc. will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Two Sigma Investments LP lifted its stake in shares of Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after buying an additional 5,955 shares during the period. Geode Capital Management LLC grew its position in Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after buying an additional 18,213 shares in the last quarter. State Street Corp bought a new position in Traws Pharma during the fourth quarter valued at about $29,000. XTX Topco Ltd increased its stake in Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after acquiring an additional 31,502 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new position in Traws Pharma in the 4th quarter valued at approximately $56,000. Institutional investors own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.